Trends in female breast cancer incidence, mortality, and survival in Austria, with focus on age, stage, and birth cohorts (1983-2017).


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
29 04 2022
Historique:
received: 23 12 2021
accepted: 28 03 2022
entrez: 29 4 2022
pubmed: 30 4 2022
medline: 4 5 2022
Statut: epublish

Résumé

Breast cancer (BC) is the most commonly diagnosed malignant disease and the leading cause of cancer death in women in Austria. We investigated overall and subgroup-specific female breast cancer rates to provide a comprehensive analysis of trends over several decades. Incidence, mortality, and survival, as well as age-, stage-, and birth cohort-specific incidence were analysed using nationwide cancer registry data on 163,694 cases of female breast cancer in Austria (1983-2017). Annual percentage changes were estimated using joinpoint regression. BC incidence underwent linear increases until 1997 and reversed with statistically non-significant declines until 2017. After initial increases in BC-specific mortality, rates were stable from 1989 through 1995 and started declining thereafter, although statistically non-significantly after 2011. Overall BC-specific survivals, as well as survivals according to the calendar period of diagnosis, increased throughout the observation period. Incidence in younger women (aged 44 and lower) showed linear increases, whereas for women aged 45 and higher mostly stable or decreasing rates were observed. Localised BC incidence increased markedly and started declining only in 2012. Distant disease-BC incidence decreased through the whole observation period and incidence of regionalised BC started declining in 2000. Birth cohort-specific incidence peaked in women born between 1935 and 1949 (ages 45-74). In conclusion, the incidence of BC in younger women is increasing, while overall female BC incidence and mortality are stable with non-significant declines. Further, increases in the incidence of early-stage BC (localised) seem disproportionately high in comparison to more modest decreases in late-stage BC incidence (regionalised and distant disease).

Identifiants

pubmed: 35487918
doi: 10.1038/s41598-022-10560-x
pii: 10.1038/s41598-022-10560-x
pmc: PMC9054853
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

7048

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2022. The Author(s).

Références

JAMA Netw Open. 2020 Aug 3;3(8):e2013226
pubmed: 32804214
Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1495-506
pubmed: 26359465
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Ann Oncol. 2012 Jun;23(6):1394-402
pubmed: 22234738
Br J Cancer. 2012 Mar 13;106(6):1068-75
pubmed: 22382691
Eur J Cancer Prev. 2006 Aug;15(4):343-6
pubmed: 16835504
Lancet Glob Health. 2020 Aug;8(8):e1027-e1037
pubmed: 32710860
JNCI Cancer Spectr. 2019 Jun 07;3(3):pkz040
pubmed: 31392297
N Engl J Med. 2005 Oct 27;353(17):1784-92
pubmed: 16251534
Breast Cancer (Dove Med Press). 2021 Apr 13;13:241-257
pubmed: 33883932
Breast Cancer Res Treat. 2019 Feb;173(3):743-747
pubmed: 30426307
Epidemiology. 2006 Jan;17(1):108-11
pubmed: 16357603
Environ Health Perspect. 2017 Oct 13;125(10):107005
pubmed: 29033383
N Engl J Med. 2012 Nov 22;367(21):1998-2005
pubmed: 23171096
BMC Med Res Methodol. 2011 Sep 19;11:129
pubmed: 21929796
Eur J Cancer. 2018 Feb;90:34-62
pubmed: 29272783
J Intern Med. 2006 Aug;260(2):103-17
pubmed: 16882274
Value Health. 2017 Sep;20(8):1048-1057
pubmed: 28964436
CA Cancer J Clin. 2019 Nov;69(6):438-451
pubmed: 31577379
Cancer Causes Control. 2010 Jan;21(1):83-90
pubmed: 19795215
N Engl J Med. 2016 Oct 13;375(15):1438-1447
pubmed: 27732805
Breast. 2015 Apr;24(2):112-7
pubmed: 25522906
Stat Methods Med Res. 2006 Dec;15(6):547-69
pubmed: 17260923

Auteurs

Lazo Ilic (L)

Department of Social and Preventive Medicine, Center for Public Health, Medical University of Vienna, Kinderspitalgasse 15, 1090, Vienna, Austria. lazo.ilic@muv.ac.at.
Department of Health Economics, Center for Public Health, Medical University of Vienna, Kinderspitalgasse 15, 1090, Vienna, Austria. lazo.ilic@muv.ac.at.

Gerald Haidinger (G)

Department of Social and Preventive Medicine, Center for Public Health, Medical University of Vienna, Kinderspitalgasse 15, 1090, Vienna, Austria.

Judit Simon (J)

Department of Health Economics, Center for Public Health, Medical University of Vienna, Kinderspitalgasse 15, 1090, Vienna, Austria.

Monika Hackl (M)

Austrian National Cancer Registry, Statistics Austria, Guglgasse 13, 1110, Vienna, Austria.

Eva Schernhammer (E)

Department of Epidemiology, Center for Public Health, Medical University of Vienna, Kinderspitalgasse 15, 1090, Vienna, Austria.

Kyriaki Papantoniou (K)

Department of Epidemiology, Center for Public Health, Medical University of Vienna, Kinderspitalgasse 15, 1090, Vienna, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH